Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 03

Next Previous
Drug Profile

CB 03

Alternative Names: CB-003 - Zhimeng Biopharma; CB-03; CB03-154

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhimeng Biopharma
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Mood stabilisers; Small molecules; Vascular disorder therapies
  • Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Amyotrophic lateral sclerosis
  • Phase II Epilepsy; Major depressive disorder
  • Phase I Bipolar disorders
  • Preclinical Stroke
  • No development reported Pain

Most Recent Events

  • 31 Oct 2025 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Zhimeng Biopharma
  • 11 Sep 2025 NMPA approves IND application for CB-03 in Epilepsy
  • 11 Sep 2025 Zhimeng Biopharma plans a phase-II trial for Epilepsy (Adjunctive therapy) in China (PO), (NCT06612775)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top